LONDON, July 16, 2026 /PRNewswire/ – Virax Biolabs Group Limited (Nasdaq: VRAX) has published a shareholder update providing context on several recent developments, including the filing of its fiscal 2026 Annual Report, the multi-country commercial supply agreement with Fosun Diagnostics for ImmuneSelect across six Southeast Asian markets, the completion of a preferred investment option exercise generating approximately $3.3 million in gross proceeds, and the restoration of Nasdaq minimum bid price compliance. The update also outlines the Company’s priorities for ViraxImmune™, ImmuneSelect and continued commercial execution.
